Once-Daily Opicapone Adds ' On Time ' in PD Phase 3 Studies Once-Daily Opicapone Adds ' On Time ' in PD Phase 3 Studies

A new COMT inhibitor in development with more convenient dosing is evaluated for safety and efficacy in people with Parkinson ' s disease and motor fluctuations.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news